Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fangmeng Fu

Showing results (81-90 of 90) with videos related to

Pageof 9
Sort By:
You have reached the last page of results.This site can display upto 90 results.
Cell Death & Disease|July 18, 2024
MAZ-mediated up-regulation of BCKDK reprograms glucose metabolism and promotes growth by regulating glucose-6-phosphate dehydrogenase stability in triple-negative breast cancerYan Li, Yuxiang Lin, Yali Tang, et al.
International Journal of Cancer|May 5, 2025
Timing of surgery and 1-year postoperative outcomes in patients with breast cancer and preoperative COVID-19 history: A matched, longitudinal, ambidirectional cohort studyYali Wang, Lijuan He, Minyan Chen, et al.
Theranostics|February 4, 2021
Large-scale tumor-associated collagen signatures identify high-risk breast cancer patientsGangqin Xi, Wenhui Guo, Deyong Kang, et al.
BMC Cancer|November 3, 2022
Clinical application of artificial neural network (ANN) modeling to predict BRCA1/2 germline deleterious variants in Chinese bilateral primary breast cancer patientsYan Li, Lili Chen, Jinxing Lv, et al.
The American Journal of Surgical Pathology|December 20, 2023
Prognostic Value of Immunohistochemistry-based Subtyping Before and After Neoadjuvant Chemotherapy in Patients with Triple-negative Breast CancerLong Wu, Minyan Chen, Yuxiang Lin, et al.
JAMA Network Open|February 15, 2022
Association of Adjuvant Hormone Therapy Timing With Overall Survival Among Patients With Hormone Receptor-Positive Human Epidermal Growth Factor Receptor-2-Negative Early Breast Cancer Without ChemotherapyFangmeng Fu, Liuwen Yu, Bangwei Zeng, et al.
BMC Cancer|April 25, 2023
High leukocyte mitochondrial DNA copy number contributes to poor prognosis in breast cancer patientsWenzhe Zhang, Songping Lin, Bangwei Zeng, et al.
Cancer Science|October 14, 2024
Identification of sequence polymorphism in the D-loop region of mitochondrial DNA as a risk factor for breast cancerQian Nie, Wenzhe Zhang, Songping Lin, et al.
Frontiers in Oncology|April 2, 2021
Assessment of CPS + EG, Neo-Bioscore and Modified Neo-Bioscore in Breast Cancer Patients Treated With Preoperative Systemic Therapy: A Multicenter Cohort StudyLing Xu, Yinhua Liu, Zhimin Fan, et al.
The Lancet. Oncology|July 1, 2026
Trastuzumab rezetecan versus pyrotinib plus capecitabine for patients with HER2-positive metastatic breast cancer (HORIZON-Breast01): interim analysis of a multicentre, open-label, randomised, controlled, phase 3 trialHerui Yao, Qingyuan Zhang, Huiping Li, et al.
Pageof 9

Showing results (81-90 of 90) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 90 results.
Cell Death & Disease|July 18, 2024
MAZ-mediated up-regulation of BCKDK reprograms glucose metabolism and promotes growth by regulating glucose-6-phosphate dehydrogenase stability in triple-negative breast cancerYan Li, Yuxiang Lin, Yali Tang, et al.
International Journal of Cancer|May 5, 2025
Timing of surgery and 1-year postoperative outcomes in patients with breast cancer and preoperative COVID-19 history: A matched, longitudinal, ambidirectional cohort studyYali Wang, Lijuan He, Minyan Chen, et al.
Theranostics|February 4, 2021
Large-scale tumor-associated collagen signatures identify high-risk breast cancer patientsGangqin Xi, Wenhui Guo, Deyong Kang, et al.
BMC Cancer|November 3, 2022
Clinical application of artificial neural network (ANN) modeling to predict BRCA1/2 germline deleterious variants in Chinese bilateral primary breast cancer patientsYan Li, Lili Chen, Jinxing Lv, et al.
The American Journal of Surgical Pathology|December 20, 2023
Prognostic Value of Immunohistochemistry-based Subtyping Before and After Neoadjuvant Chemotherapy in Patients with Triple-negative Breast CancerLong Wu, Minyan Chen, Yuxiang Lin, et al.
JAMA Network Open|February 15, 2022
Association of Adjuvant Hormone Therapy Timing With Overall Survival Among Patients With Hormone Receptor-Positive Human Epidermal Growth Factor Receptor-2-Negative Early Breast Cancer Without ChemotherapyFangmeng Fu, Liuwen Yu, Bangwei Zeng, et al.
BMC Cancer|April 25, 2023
High leukocyte mitochondrial DNA copy number contributes to poor prognosis in breast cancer patientsWenzhe Zhang, Songping Lin, Bangwei Zeng, et al.
Cancer Science|October 14, 2024
Identification of sequence polymorphism in the D-loop region of mitochondrial DNA as a risk factor for breast cancerQian Nie, Wenzhe Zhang, Songping Lin, et al.
Frontiers in Oncology|April 2, 2021
Assessment of CPS + EG, Neo-Bioscore and Modified Neo-Bioscore in Breast Cancer Patients Treated With Preoperative Systemic Therapy: A Multicenter Cohort StudyLing Xu, Yinhua Liu, Zhimin Fan, et al.
The Lancet. Oncology|July 1, 2026
Trastuzumab rezetecan versus pyrotinib plus capecitabine for patients with HER2-positive metastatic breast cancer (HORIZON-Breast01): interim analysis of a multicentre, open-label, randomised, controlled, phase 3 trialHerui Yao, Qingyuan Zhang, Huiping Li, et al.
Pageof 9